ReParris introduces first-in-class small molecules designed to regenerate tissues and reduce inflammation behind age-related diseases. With examples in pulmonary fibrosis and sepsis, this initiative offers a fresh perspective on extending healthspan. As highlighted in PR Newswire’s release, embracing regulatory reform can accelerate these advancements—an actionable insight for healthcare innovators.